Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||uveal melanoma||not applicable||Cabozantinib||Phase II||Actionable||In a Phase II trial, treatment with Cometriq (Cabometyx, cabozantinib) did not result in an improved progression-free survival at 4 months (32.3% vs 26.7%, P=0.35) and median overall survival (6.4 mo vs 7.3 mo, P=0.58) when compared to treatment with Temodar (temozolomide) or Deticene (dacarbazine) in patients with uveal melanoma (PMID: 31558480; NCT01835145).||31558480|
|Unknown unknown||uveal melanoma||not applicable||Cabozantinib||Phase II||Actionable||In a Phase II trial, Cometriq (cabozantinib) treatment resulted in stable disease in 61% (14/23) of patients with metastatic uveal melanoma, with a median progression free survival of 4.8 months and an overall survival of 12.6 months (PMID: 28103611; NCT00940225).||28103611|
|PubMed Id||Reference Title||Details|
|(28103611)||Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.||Full reference...|
|(31558480)||Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).||Full reference...|